Pramila Krishnamurthy

Denmark Hill
London, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 33 publications

DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.

DDX41-mutant myeloid neoplasms defy current prognostic schemes and require a dedicated risk scoring system: a multicenter, retrospective study.

Journal: Leukemia
Published: May 24, 2025

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.

Pivotal results of SELECT-MDS-1 phase 3 study of tamibarotene with azacitidine in newly diagnosed higher-risk MDS.

Journal: Blood advances
Published: February 24, 2025

Venetoclax-based non-intensive combinations for relapsed/refractory acute myeloid leukaemia-Real-world data from a UK-wide programme.

Venetoclax-based non-intensive combinations for relapsed/refractory acute myeloid leukaemia-Real-world data from a UK-wide programme.

Journal: British journal of haematology
Published: January 21, 2025

Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) trial: study protocol for a multicentre, double-blinded, placebo-controlled, phase IIa trial.

Intestinal Microbiota Transplant Prior to Allogeneic Stem Cell Transplant (MAST) trial: study protocol for a multicentre, double-blinded, placebo-controlled, phase IIa trial.

Journal: BMJ open
Published: January 08, 2025

Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.

Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.

Journal: Blood advances
Published: June 18, 2024

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS.

Real-world outcomes of newly diagnosed AML treated with venetoclax and azacitidine or low-dose cytarabine in the UK NHS.

Journal: Blood neoplasia
Published: April 15, 2024

Disseminated Mucormycosis and T-Cell-Depleted Allogeneic Stem Cell Transplantation: An Unusual Case Study.

Disseminated Mucormycosis and T-Cell-Depleted Allogeneic Stem Cell Transplantation: An Unusual Case Study.

Journal: Acta haematologica
Published: March 19, 2024

A patient with widespread firm nontender nodules.

A patient with widespread firm nontender nodules.

Journal: JAAD case reports
Published: July 26, 2023

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.

Molecular MRD is strongly prognostic in patients with NPM1-mutated AML receiving venetoclax-based nonintensive therapy.

Journal: Blood
Published: June 20, 2023

Double, double, TP53, and trouble in myelofibrosis.

Double, double, TP53, and trouble in myelofibrosis.

Journal: Blood
Published: June 08, 2023

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.

FLT3 inhibitors as MRD-guided salvage treatment for molecular failure in FLT3 mutated AML.

Journal: Leukemia
Published: May 30, 2023

Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients.

Myeloablative Dose of Busulfan and Fludarabine Combined with In Vivo T Cell Depletion Is Safe and Effective Conditioning for Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients.

Journal: Transplantation and cellular therapy
Published: April 10, 2023
Showing 1-12 of 33

Last Updated: 09/26/2026